Marc Tessier-Lavigne Insider Trading $DNLI Denali Therapeutics Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Marc Tessier-Lavigne.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Marc Tessier-Lavigne. Marc Tessier-Lavigne is EVP, RESEARCH DRUG DISCOVERY in GENENTECH INC ($DNA) and Director in PFIZER INC ($PFE) and Director in REGENERON PHARMACEUTICALS INC ($REGN) and Director in AGIOS PHARMACEUTICALS INC ($AGIO) and Director in Juno Therapeutics, Inc. ($JUNO) and Director in Denali Therapeutics Inc. ($DNLI).
Marc Tessier-Lavigne in Denali Therapeutics Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Marc Tessier-Lavigne: Director
Holdings: 2,544,370 shares
Latest Transaction: Jun 04 2021
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of Marc Tessier-Lavigne in Denali Therapeutics Inc.
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AGIO, DNLI, DNA, JUNO, PFE, REGN
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 04 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 63.76 | 6,222 | 396,715 | 6,222 | |
| Jun 04 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Grant | A | 0.00 | 2,074 | 0 | 2,544,370 | 2.5 M to 2.5 M (+0.08 %) |
| May 24 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 60.03 | 8,806 | 528,580 | 2,542,296 | 2.6 M to 2.5 M (-0.35 %) |
| May 24 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 60.13 | 37,957 | 2,282,468 | 2,551,102 | 2.6 M to 2.6 M (-1.47 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 71.35 | 1,031 | 73,563 | 2,642,296 | 2.6 M to 2.6 M (-0.04 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 69.59 | 3,482 | 242,309 | 2,643,327 | 2.6 M to 2.6 M (-0.13 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 68.50 | 6,011 | 411,778 | 2,646,809 | 2.7 M to 2.6 M (-0.23 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 67.57 | 14,945 | 1,009,834 | 2,652,820 | 2.7 M to 2.7 M (-0.56 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 66.55 | 18,316 | 1,219,003 | 2,667,765 | 2.7 M to 2.7 M (-0.68 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 65.63 | 37,445 | 2,457,665 | 2,686,081 | 2.7 M to 2.7 M (-1.37 %) |
| Mar 03 2021 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 64.36 | 18,770 | 1,208,056 | 2,723,526 | 2.7 M to 2.7 M (-0.68 %) |
| Jun 18 2020 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 26.10 | 400,000 | 10,440,000 | 2,739,043 | 3.1 M to 2.7 M (-12.74 %) |
| Jun 18 2020 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Sell | S | 26.10 | 400,000 | 10,440,000 | 2,739,043 | 3.1 M to 2.7 M (-12.74 %) |
| Jun 05 2020 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 0.00 | 3,253 | 0 | 3,253 | |
| Jun 05 2020 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 28.82 | 15,183 | 437,574 | 15,183 | |
| May 31 2019 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 19.50 | 27,245 | 531,278 | 27,245 | |
| Jun 15 2018 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 18.92 | 27,830 | 526,544 | 27,830 | |
| Dec 12 2017 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | C | 0.00 | 25,000 | 0 | 0 | |
| Dec 12 2017 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Buy | C | 0.00 | 25,000 | 0 | 3,139,043 | 3.1 M to 3.1 M (+0.80 %) |
| Dec 08 2017 | DNLI | Denali Therapeutic ... | Tessier-Lavigne Marc | Director | Option Exercise | A | 18.00 | 47,165 | 848,970 | 47,165 |
Page: 1